Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

521
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
521
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

858
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

822
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
822
Glucose Homeostasis: Regulation of Blood Glucose01:02

Glucose Homeostasis: Regulation of Blood Glucose

3.8K
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
3.8K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

593
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
593

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cost-effectiveness of control-IQ automated insulin delivery in adults with type 1 diabetes in Sweden.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Cost-Effectiveness of Control-IQ+ Technology in Insulin-Treated Patients With Type 2 Diabetes in the United States.

Diabetes, obesity & metabolism·2026
Same author

Safety of Inhaled Insulin in Adults with Diabetes.

Diabetes technology & therapeutics·2026
Same author

A Real-World Data Assessment of Pulmonary Toxicity of Inhaled Insulin for Diabetes.

Diabetes technology & therapeutics·2026
Same author

Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.

Diabetes, obesity & metabolism·2026
Same author

Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.

Frontiers in endocrinology·2026

相关实验视频

Updated: Jan 13, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.3K

通过控制IQ技术实现了HEDIS的血糖目标.

Bimal V Patel, Sharon M Wang1, Laurel H Messer

  • 1Tandem Diabetes Care, 12400 High Bluff Dr, San Diego, CA 92130.

The American journal of managed care
|January 9, 2026
PubMed
概括

切换到自动胰岛素输送 (AID) 疗法显著改善了1型糖尿病 (T1D) 患者的血糖控制. 更多的患者实现了目标葡萄糖水平,减少了血糖控制不良的情况.

更多相关视频

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.4K
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.5K

相关实验视频

Last Updated: Jan 13, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.3K
A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.4K
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.5K

科学领域:

  • 内分泌学和新陈代谢学
  • 糖尿病 技术 技术
  • 公共卫生和质量措施

背景情况:

  • 1型糖尿病 (T1D) 的管理通常涉及多次每日胰岛素注射 (MDI).
  • 自动化胰岛素输送系统 (AID) 提供先进的血糖控制解决方案.
  • 医疗保健有效性数据和信息集 (HEDIS) 的措施使用HbA1c和葡萄糖管理指标 (GMI) 评估血糖状况.

研究的目的:

  • 评估从MDI切换到控制-IQ AID对T1D的血糖控制的影响.
  • 为了评估12个月过渡后葡萄糖管理指标 (GMI) 和血红蛋白A1c (HbA1c) 的变化.
  • 为了比较HEDIS和美国糖尿病协会 (ADA) 的血糖目标在不同类型的付款人之间.

主要方法:

  • 对12522名T1D患者的美国数据进行了回顾性分析.
  • 纳入标准:先前使用MDI,在控制IQ上≥1年,在开始后6个月内使用基线HbA1c,并使用≥70%的连续血糖监测.
  • 主要结果:满足HEDIS (<8%HbA1c/GMI) 和ADA (<7%GMI) 目标的比例变化,按付款人 (商业,医疗补助,医疗保险) 分析.

主要成果:

  • 满足HEDIS质量标准的显著改善,在AID启动后12个月内从49.6%增加到92.9%.
  • 在那些达到<7%的GMI.的人群中也观察到类似的改善.
  • 血糖控制不良的急剧减少 (HbA1c >9%),在所有付款人群中从3431人减少到15人 (减少99.6%).

结论:

  • 与MDI相比,控制智商辅助治疗使得T1D患者的比例大大提高,能够达到血糖目标.
  • 改善的血糖控制在商业,医疗补助和医疗保险支付人群中是一致的.
  • 艾滋病辅助技术在实现T1D患者最佳血糖状况方面取得了重大进展.